Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
18 Marzo 2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05 Marzo 2024
PAST, PRESENT, FUTURE
15 Febbraio 2024
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
08 Gennaio 2024
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
19 Dicembre 2023
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
18 Dicembre 2023
Restore to Impact | Award Ceremony
14 Dicembre 2023
Chiesi explores the impact of climate change on people living with respiratory conditions in the series “The Climate and Us”
05 Dicembre 2023
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
